Related Experiment Video
Updated: Sep 19, 2025

An In Vitro Dissolution Determination of Multi-Index Components in Tibetan Medicine Rhodiola Granules
Published on: November 4, 2022
Quantitative evaluation and obstacle factor diagnosis of drug regulatory capacity in China
Mingming Zhai1, Liwen Huang2, Shijie Sun1
1School of Medical Devices, Shenyang Pharmaceutical University, Shenyang.
Objective:
To quantitatively evaluate the drug regulatory capacity in China, aiming to optimize the drug regulatory system, precisely enhance local regulatory effectiveness, and reduce regional regulatory disparities.
Methods:
Using the methods of literature research, expert interviews, investigation and analysis, the quantitative evaluation indicator system of supervision ability was established in all directions; the indicator data were collected and quantified; the indicator weight setting algorithm of the evaluation system was improved and the indicator weight was set by combining AHP and entropy method; the differences among eastern, central, and western provincial-level regions were analyzed by variance analysis; panel data were constructed for spatio-temporal evolution analysis; obstacle factor diagnosis model was used to analyze the obstacle factors.
Results:
The quantitative indicator system was constructed from five aspects: resource acquisition, function performance, learning and development, performance level and Internet application,and the relevant indicators of pharmacovigilance and risk response were analyzed at the national macro level. From the analysis of horizontal comparative variance, the comprehensive indicator and resource acquisition indicator of various provincial-level regions were significantly different(P < 0.05), while others were not significant. From the perspective of dynamic development, except for the performance level in 2022, all provincial-level regions were generally on the rise. From the perspective of obstacle factors, they were mainly in the aspects of learning development and functional performance. Regarding national pharmacovigilance and risk response, despite the synergistic development of all links ensuring drug safety and promoting industrial progress, new issues and challenges demand continuous attention and optimization of the regulatory system.
Conclusion:
There are regional differences in drug regulation in China. A drug regulation capacity improvement plan should be formulated in combination with the characteristics of the city itself and obstacle factors to achieve efficient and balanced development of drug regulation.
More Related Videos
09:16Author Spotlight: Optimization of Processing Technology for Tiebangchui with Zanba Based on CRITIC Combined with Box-Behnken Response Surface Method
Published on: May 12, 2023
05:47In Silico Modeling Method for Computational Aquatic Toxicology of Endocrine Disruptors: A Software-Based Approach Using QSAR Toolbox
Published on: August 28, 2019
Related Concept Videos
Drug Regulation
Drug Control Governance: Regulatory Bodies and Their Impact
Pharmacovigilance
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
Clinical Trials: Overview
Preclinical Development: Overview
Analysis of Population Pharmacokinetic Data